Early Study of CYNK-001 Expands to Include R/R Acute Myeloid Leukemia Cohort
June 29th 2021Patients with relapsed/refractory acute myeloid leukemia will now be assesses with the off-the-shelf cell therapy CYNK-001 after a case of conversion to minimal residual disease negativity at its highest dose level.
AMG 757 Elicits Early Response, Safety in Small Cell Lung Cancer
June 18th 2021First-in-human results of a phase 1 trial (NCT03319940) evaluating AMG 757 in patients with small cell lung cancer revealed early signals of efficacy and a favorable safety profile in findings presented at the European Lung Cancer Virtual Congress 2021.
Pimitespib Shows Significant PFS Improvement in Advanced Refractory GIST
June 8th 2021Pimitespib, a heat shock protein 90 inhibitor doubled the progression-free survival and prolonged the overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib, according to results from the phase 3 CHAPTER-GIST-301 trial.
Pertuzumab Plus Trastuzumab Demonstrates Clinical Activity in ERBB2/ERBB3+ Uterine Cancer
June 7th 2021In patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer, the combination of pertuzumab and trastuzumab led to a 37% disease control rate, according to results from the Targeted Agent Profiling and Utilization Registry study.
Adjuvant Pembrolizumab Significantly Reduces Risk of Disease Recurrence or Death in RCC
June 3rd 2021Data from the phase 3 KEYNOTE-564 trial presented in a press briefing ahead of the 2021 ASCO Annual Meeting showed that adjuvant pembrolizuumab achieved significant disease-free survival improvement compared with placebo.
Liso-Cel for Patients With R/R LBCL Shows Promising Results in Real-World Settings
May 15th 2021Patients with relapsed or refractory aggressive large B-cell lymphoma showed promising results from the administration of lisocabtagene maraleucel in both inpatient and outpatient non–university hospital settings.
Study Identifies Ideal Ixazomib Triplet Regimen for Newly Diagnosed Multiple Myeloma
April 15th 2021Ixazomib plus cyclophosphamide, and dexamethasone elicited higher rates of efficacy compared with ixazomib/dexamethasone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma/
Teclistamab Demonstrates High Response Rate and Good Tolerability in Multiple Myeloma
April 14th 2021Investigators reported an objective response rate of 73% for the anti–B-cell maturation antigen teclistamab in patients with relapsed/ refractory multiple myeloma, according to results from an ongoing study.
Lenalidomide Reduces Infection Mortality Rates in COVID-19-Positive Patients With Multiple Myeloma
April 13th 2021Infection mortality rate were lower in patients with multiple myeloma who were coronavirus disease 2019 positive and received maintenance lenalidomide than those who did not receive lenalidomide, according to study results presented during the 2nd European Myeloma Network Meeting.
Copanlisib Plus Rituximab Extends Progression-Free Survival in Indolent NHL
April 10th 2021Primary results from the phase 3 CHRONOS-3 study revealed a survival benefit with the combination of copanlisib in combination with rituximab over rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.
Orca-T Reduces GVHD, Mortalities in Hematologic Malignancies
March 28th 2021Data presented during the 2021 Transplantation and Cellular Therapy Meetings showed that treatment with Orca-T achieved a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, and a lack of treatment-related mortalities while demonstrating scalability potential.
Cabozantinib Induces Intracranial/Extracranial Responses in Metastatic RCC
February 13th 2021In patient with metastatic renal cell carcinoma who have brain metastases, treatment with cabozantinib displayed significant intracranial and extracranial, results from a retrospective analysis presented during the 2021 Genitourinary Cancers Symposium show.
Japanese Patients With Urothelial Cancer Benefit From Frontline Avelumab Maintenance Addition
February 11th 2021A subgroup analysis from the phase 3 JAVELIN Bladder 100 trial demonstrated that Japanese patients with advanced urothelial cancer whose disease did not progress on frontline chemotherapy benefited from the addition of avelumab to best supportive care in the first-line maintenance setting.
Narsoplimab Demonstrates Clinical Activity in High-Risk HSCT-TMA
February 9th 2021In a pivotal phase 2 trial, administration of narsoplimab to patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy led to impressive responses and a favorable survival benefit.
Addition of Ipilimumab to Pembrolizumab Not Additive in Frontline PD-L1–High NSCLC
January 31st 2021Survival was not improved with the immunotherapy combination of pembrolizumab and ipilimumab in comparison with pembrolizumab monotherapy in the first-line treatment of patients with metastatic non–small cell lung cancer who had high PD-L1 expression and did not harbor EGFR or ALK aberrations, findings from the phase 3 KEYNOTE-598 trial showed.
Sotorasib Impresses in KRAS G12C–Mutant Non–Small Cell Lung Cancer
January 29th 2021Sotorasib demonstrated significant benefit in patients with KRAS G12C–mutated advanced non–small cell lung cancer, according to results from the phase 2 portion of the CodeBreaK 100 trial to be presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer.
Ivosidenib Improves Overall Survival in Advanced IDH1+ Cholangiocarcinoma
January 17th 2021The final overall survival analysis of the phase 3 ClarIDHy trial demonstrated that treatment with ivosidenib tablets achieved a 21% reduction in the risk of death in patients with IDH1-mutant cholangiocarcinoma compared with placebo.